| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2002PNAS...99..937F |
| P356 | DOI | 10.1073/PNAS.241629998 |
| P8608 | Fatcat ID | release_omiradygnzcsrbpyy3bak6dl2m |
| P932 | PMC publication ID | 117409 |
| P698 | PubMed publication ID | 11782540 |
| P5875 | ResearchGate publication ID | 11574851 |
| P50 | author | Alan Fersht | Q537479 |
| Dmitry B Veprintsev | Q42290924 | ||
| Lars O. Hansson | Q57779013 | ||
| Stefan Rüdiger | Q64681813 | ||
| P2093 | author name string | Assaf Friedler | |
| Mark R Proctor | |||
| Penka V Nikolova | |||
| Stefan M V Freund | |||
| Thomas M Rippin | |||
| P2860 | cites work | ASPP proteins specifically stimulate the apoptotic function of p53 | Q24291844 |
| Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2 | Q24314736 | ||
| Stimulation of p53-mediated transcriptional activation by the p53-binding proteins, 53BP1 and 53BP2 | Q24316208 | ||
| Proapoptotic p53-interacting protein 53BP2 is induced by UV irradiation but suppressed by p53 | Q24551160 | ||
| Two cellular proteins that bind to wild-type but not mutant p53 | Q24562261 | ||
| Thermodynamic stability of wild-type and mutant p53 core domain | Q24648879 | ||
| Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations | Q27730815 | ||
| SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling | Q27860614 | ||
| Rescuing the function of mutant p53. | Q30329984 | ||
| p53 and human cancer: the first ten thousand mutations. | Q33767112 | ||
| Strategies for manipulating the p53 pathway in the treatment of human cancer. | Q34076012 | ||
| The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity | Q34252975 | ||
| Hot-spot mutants of p53 core domain evince characteristic local structural changes. | Q35549859 | ||
| Identification of an additional negative regulatory region for p53 sequence-specific DNA binding | Q37379743 | ||
| Regulation of the sequence-specific DNA binding function of p53 by protein kinase C and protein phosphatases | Q38297819 | ||
| Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. | Q39445499 | ||
| Quantitative analysis of residual folding and DNA binding in mutant p53 core domain: definition of mutant states for rescue in cancer therapy | Q40774297 | ||
| Competition BIAcore for measuring true affinities: large differences from values determined from binding kinetics. | Q52310418 | ||
| Small peptides activate the latent sequence-specific DNA binding function of p53. | Q54601436 | ||
| Restoration of the transcription activation function to mutant p53 in human cancer cells | Q71865200 | ||
| Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells | Q73212113 | ||
| Pharmacological rescue of mutant p53 conformation and function | Q73316566 | ||
| Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain | Q73400021 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | molecular chaperones | Q422496 |
| P1104 | number of pages | 6 | |
| P304 | page(s) | 937-942 | |
| P577 | publication date | 2002-01-08 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants | |
| P478 | volume | 99 |
| Q35181792 | A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity |
| Q39795567 | A peptidomimetic approach to targeting pre-amyloidogenic states in type II diabetes |
| Q52579544 | APR-246 reactivates mutant p53 by targeting cysteines 124 and 277. |
| Q28299046 | ASPP [corrected] and cancer |
| Q31090644 | ASPP: a new family of oncogenes and tumour suppressor genes |
| Q56341291 | Aggregation-primed molten globule conformers of the p53 core domain provide potential tools for studying p53C aggregation in cancer |
| Q36017772 | Apoptosis-based therapies and drug targets |
| Q51564147 | Binding of Rad51 and other peptide sequences to a promiscuous, highly electrostatic binding site in p53. |
| Q57890248 | Bioactive Natural Peptides |
| Q38911627 | CP-31398 prevents the growth of p53-mutated colorectal cancer cells in vitro and in vivo |
| Q24800091 | CP-31398, a putative p53-stabilizing molecule tested in mammalian cells and in yeast for its effects on p53 transcriptional activity |
| Q41109894 | Chaperonin-Based Biolayer Interferometry To Assess the Kinetic Stability of Metastable, Aggregation-Prone Proteins |
| Q48243773 | Characterization of an Hsp90-Independent Interaction between Co-Chaperone p23 and Transcription Factor p53. |
| Q26863501 | Chemotherapeutic compounds targeting the DNA double-strand break repair pathways: the good, the bad, and the promising |
| Q38472585 | Compensated pathogenic deviations |
| Q21284221 | Computational genes: a tool for molecular diagnosis and therapy of aberrant mutational phenotype |
| Q24628577 | Computational identification of a transiently open L1/S3 pocket for reactivation of mutant p53 |
| Q57785253 | Constructing Kinetically Controlled Denaturation Isotherms of Folded Proteins Using Denaturant-Pulse Chaperonin Binding |
| Q73747386 | Cooperative organization in a macromolecular complex |
| Q27642314 | Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations |
| Q33727544 | Cyclic peptide inhibitors of HIV-1 integrase derived from the LEDGF/p75 protein |
| Q33777703 | Deciphering the folding transition state structure and denatured state properties of nucleophosmin C-terminal domain |
| Q73073429 | Design and characterization of a hyperstable p16INK4a that restores Cdk4 binding activity when combined with oncogenic mutations |
| Q21030644 | Determining biophysical protein stability in lysates by a fast proteolysis assay, FASTpp |
| Q35101871 | Drug discovery and p53. |
| Q51186530 | Effects of common cancer mutations on stability and DNA binding of full-length p53 compared with isolated core domains. |
| Q36547790 | Exploiting the p53 pathway for the diagnosis and therapy of human cancer. |
| Q37808312 | From peptides to proteins: lessons from my years at the Centre for Protein Engineering |
| Q38778367 | Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma. |
| Q33275131 | High-throughput screening for human lysosomal beta-N-Acetyl hexosaminidase inhibitors acting as pharmacological chaperones |
| Q30009145 | Highly homologous proteins exert opposite biological activities by using different interaction interfaces |
| Q51026030 | In vitro folding and characterization of the p53 DNA binding domain. |
| Q35850134 | Inhibiting HIV-1 integrase by shifting its oligomerization equilibrium |
| Q58322007 | Kinetic Instability of p53 Core Domain Mutants |
| Q36187316 | Kinetic mechanism of p53 oncogenic mutant aggregation and its inhibition |
| Q81820580 | Knockdown of p53 levels in human keratinocytes accelerates Mcl-1 and Bcl-x(L) reduction thereby enhancing UV-light induced apoptosis |
| Q29547663 | Live or let die: the cell's response to p53 |
| Q39379988 | Molecular basis of the interaction between proapoptotic truncated BID (tBID) protein and mitochondrial carrier homologue 2 (MTCH2) protein: key players in mitochondrial death pathway |
| Q24336091 | Molecular basis of the interaction between the antiapoptotic Bcl-2 family proteins and the proapoptotic protein ASPP2 |
| Q42088517 | Molecular mechanisms of functional rescue mediated by P53 tumor suppressor mutations |
| Q36066191 | Molecular neuro-oncology and the development of targeted therapeutic strategies for brain tumors. Part 4: p53 signaling pathway |
| Q41677793 | Multisite aggregation of p53 and implications for drug rescue |
| Q39460398 | Mutant p53 drives multinucleation and invasion through a process that is suppressed by ANKRD11. |
| Q36661775 | Mutant p53 proteins: between loss and gain of function |
| Q41968106 | Mutant p53 targeting by the low molecular weight compound STIMA-1 |
| Q26770576 | Mutant p53: One, No One, and One Hundred Thousand |
| Q36070574 | Mutant p53: one name, many proteins |
| Q57950380 | Mutants of the tumour suppressor p53 L1 loop as second-site suppressors for restoring DNA binding to oncogenic p53 mutations: structural and biochemical insights |
| Q43265534 | No evidence of direct binding between ursodeoxycholic acid and the p53 DNA-binding domain |
| Q35597613 | Novel cancer therapy by reactivation of the p53 apoptosis pathway. |
| Q38212609 | Oncoapoptotic markers in oral cancer: prognostics and therapeutic perspective |
| Q38948352 | Peptides and peptidomimetics in the p53/MDM2/MDM4 circuitry - a patent review |
| Q24316120 | Peptides that bind the HIV-1 integrase and modulate its enzymatic activity--kinetic studies and mode of action |
| Q38286198 | Pharmacological reactivation of p53 as a strategy to treat cancer. |
| Q50014672 | Pharmacoperones as Novel Therapeutics for Diverse Protein Conformational Diseases |
| Q26801512 | Protein Folding and Mechanisms of Proteostasis |
| Q33935212 | Proteins of the S100 family regulate the oligomerization of p53 tumor suppressor |
| Q47833426 | Putting p53 in Context |
| Q44145204 | QM-MM simulations on p53-DNA complex: a study of hot spot and rescue mutants |
| Q36777373 | Reactivation of mutant p53: molecular mechanisms and therapeutic potential |
| Q35691573 | Regulating the p53 system through ubiquitination |
| Q30009903 | Regulation of ASPP2 interaction with p53 core domain by an intramolecular autoinhibitory mechanism |
| Q37088668 | Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide |
| Q34332782 | Rescuing cystic fibrosis transmembrane conductance regulator (CFTR)-processing mutants by transcomplementation |
| Q36710840 | Restoration of wild-type p53 function in human cancer: relevance for tumor therapy. |
| Q37818291 | Restoring p53 tumor suppressor activity as an anticancer therapeutic strategy |
| Q33795918 | SCH529074, a small molecule activator of mutant p53, which binds p53 DNA binding domain (DBD), restores growth-suppressive function to mutant p53 and interrupts HDM2-mediated ubiquitination of wild type p53 |
| Q64231035 | Simulations of mutant p53 DNA binding domains reveal a novel druggable pocket |
| Q35204556 | Small molecules that reactivate mutant p53. |
| Q33322204 | Stability of the core domain of p53: insights from computer simulations |
| Q41453979 | Stabilization of mutant p53 via alkylation of cysteines and effects on DNA binding |
| Q34740058 | Stabilization of p53 by CP-31398 inhibits ubiquitination without altering phosphorylation at serine 15 or 20 or MDM2 binding. |
| Q41792117 | Structural analysis of the interaction between Hsp90 and the tumor suppressor protein p53. |
| Q36786022 | Structural biology of the tumor suppressor p53 and cancer-associated mutants |
| Q35051686 | Structural effects of the L145Q, V157F, and R282W cancer-associated mutations in the p53 DNA-binding core domain |
| Q36777367 | Structure-function-rescue: the diverse nature of common p53 cancer mutants |
| Q27651295 | Targeted rescue of a destabilized mutant of p53 by an in silico screened drug |
| Q26770856 | Targeting Oncogenic Mutant p53 for Cancer Therapy |
| Q47291772 | Targeting mutant p53 for efficient cancer therapy. |
| Q33655329 | Targeting p53 for Novel Anticancer Therapy |
| Q28287668 | The ASPP interaction network: electrostatic differentiation between pro- and anti-apoptotic proteins |
| Q34335012 | The central region of HDM2 provides a second binding site for p53. |
| Q37808944 | The missing Zinc: p53 misfolding and cancer |
| Q27686765 | The rebel angel: mutant p53 as the driving oncogene in breast cancer |
| Q35986418 | The tumor suppressor gene TP53: implications for cancer management and therapy |
| Q37762069 | The tumor suppressor p53: from structures to drug discovery |
| Q37081504 | The use of p53 as a tool for human cancer therapy |
| Q34583882 | Therapeutic exploitation of the p53 pathway |
| Q37564522 | Therapeutic peptides for cancer therapy. Part I - peptide inhibitors of signal transduction cascades. |
| Q28255819 | To die or not to die: how does p53 decide? |
| Q24533476 | Two sequence motifs from HIF-1alpha bind to the DNA-binding site of p53. |
| Q37855887 | Using peptides to study protein-protein interactions |
| Q58760242 | Virtual screening using covalent docking to find activators for G245S mutant p53 |
| Q64101707 | Wild type p53 function in p53 mutant harboring cells by treatment with Ashwagandha derived anticancer withanolides: bioinformatics and experimental evidence |
| Q52651294 | Wild-type and cancer-related p53 proteins are preferentially degraded by MDM2 as dimers rather than tetramers. |
| Q92508193 | iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition |
| Q33511752 | p53 Amino-terminus region (1-125) stabilizes and restores heat denatured p53 wild phenotype |
| Q57929625 | p53 latency – out of the blind alley |
| Q38069463 | p53 mutations in cancer |
| Q37865050 | p53-targeted cancer pharmacotherapy: move towards small molecule compounds |
| Q45888635 | p53: balancing tumour suppression and implications for the clinic |
| Q34412182 | αA-Crystallin-derived mini-chaperone modulates stability and function of cataract causing αAG98R-crystallin |
Search more.